Welcome to our dedicated page for Immatics N.V news (Ticker: IMTX), a resource for investors and traders seeking the latest updates and insights on Immatics N.V stock.
Immatics N.V. (IMTX) is a clinical-stage biopharmaceutical leader developing T-cell redirecting immunotherapies for cancer treatment. This news hub provides investors and researchers with timely updates on groundbreaking therapies targeting solid and liquid tumors through proprietary platforms like Xpresient® and TCER® molecules.
Access consolidated coverage of press releases, clinical trial milestones, and strategic partnerships. Track developments in adoptive cell therapies and bispecific TCR molecules designed to enhance precision oncology outcomes. Our repository ensures you never miss critical updates about FDA interactions, collaborative research advancements, or pipeline expansions.
Key content categories include clinical program updates, partnership announcements with major industry players, financial disclosures, and scientific presentations. All materials are vetted for relevance to investment analysis and therapeutic innovation.
Bookmark this page for streamlined access to Immatics' latest achievements in immuno-oncology. Check regularly for authoritative reporting on their mission to redefine cancer treatment through engineered T-cell therapies.
Immatics N.V. (NASDAQ: IMTX) announced promising Phase I results from its ACTolog® program, demonstrating the feasibility and tolerability of a personalized multi-target T cell therapy for cancer. The study involved 14 patients with relapsed/refractory solid tumors, highlighting a target positivity rate of 90% and significant T cell persistence. Notably, three patients exhibited long-term disease stabilization. The results suggest further evaluation of multi-target adoptive cell therapy using potent T cell receptors, especially targeting COL6A3 exon 6 as a valuable tumor target.
Immatics N.V. (IMTX) announced preclinical success for its first TCR Bispecific program, IMA401, achieving complete remissions of human tumors in xenograft mouse models. The IMA401 target has over 5-fold higher peptide levels than traditional targets, enhancing its efficacy. Favorable pharmacokinetic properties and a significant therapeutic window were also noted. The company plans to submit an IND application for IMA401 by the end of 2021, positioning it for potential clinical development.
Immatics N.V. (NASDAQ: IMTX) has appointed Arnd Christ as its new Chief Financial Officer (CFO), effective October 1, 2020. He replaces Thomas Ulmer, who is leaving for new opportunities. Arnd Christ, formerly CFO at InflaRx, brings nearly two decades of experience in managing financial operations within public biotech companies. CEO Harpreet Singh highlighted Christ's extensive background in corporate transactions and his strategic leadership as key to advancing Immatics' objectives in T cell receptor-based therapeutics. Christ expresses excitement about contributing to the company’s promising pipeline.
On September 15, 2020, Immatics N.V. (NASDAQ: IMTX) appointed Eliot Forster, PhD, to its Board of Directors. Forster, currently CEO at F-star Therapeutics and Non-Executive Chairman of Avacta plc, brings extensive leadership experience in immuno-oncology. His addition is expected to enhance Immatics' strategic direction as it advances its T cell receptor (TCR)-based therapeutics. The company's Chairman, Peter Chambré, noted that Forster's experience will aid in achieving clinical milestones and expanding its cancer treatment pipeline.
Immatics N.V. (NASDAQ: IMTX) has announced an update on its IMA204 ACTengine® cell therapy program targeting the COL6A3 exon 6 tumor antigen, prevalent in various solid cancers. The company is progressing towards submitting an IND application to the FDA in 2021. Preclinical studies have shown two affinity-enhanced TCR candidates demonstrating high specificity and potency, with one candidate engaging both CD8+ and CD4+ T cells. IMA204 aims to effectively address the complex tumor microenvironment, providing a new approach for treating solid tumors.
Immatics N.V. (NASDAQ: IMTX) reported significant milestones following its merger with ARYA Life Science Acquisition Corp., which raised $253 million in July 2020. The company has $322 million in cash and equivalents, ensuring capital for at least 36 months. Clinical programs have expanded to Europe, with first patient treated for IMA202 and regulatory approval for IMA203. The leadership team was enhanced with the appointment of a new Chief Medical Officer. Q2 2020 revenue rose to €6.9 million, but the net loss increased to €21.3 million due to elevated R&D and G&A expenses.
Immatics N.V. (NASDAQ: IMTX) has announced the successful treatment of the first patient in the IMA202-101 clinical trial in Germany, following approval from the Paul-Ehrlich-Institute (PEI). The PEI also approved a new phase I clinical trial for the IMA203 product candidate. Moreover, three sites in Germany are actively recruiting for the IMA200 trial series, aiming to develop T cell therapies targeting cancer. These trials focus on safety, tolerability, and initial efficacy indications. Immatics is expanding its clinical footprint to enhance patient access to innovative immunotherapy options.
Immatics N.V. (NASDAQ: IMTX) announced an extension of its collaboration with UTHealth until the end of 2024. This partnership ensures Immatics exclusive access to advanced cGMP manufacturing facilities, crucial for their Adoptive Cell Therapy (ACT) clinical trials across the US and Europe. The facility can produce up to 48 ACTengine® T cell products monthly. Immatics expects this collaboration will support its early-stage clinical programs and enhance its manufacturing capabilities, as highlighted by executives from both organizations.
Immatics N.V. (NASDAQ: IMTX) announced significant changes to its Board of Directors following its recent NASDAQ listing. New members include Michael Atieh, Paul Carter, Heather Mason, and Adam Stone, who will contribute diverse expertise to advance the company's innovative T cell receptor (TCR)-based cancer therapies. Chairman Peter Chambré emphasized the importance of these developments for enhancing shareholder value and improving patient outcomes.
Immatics N.V. has successfully completed its business combination with Arya Sciences Acquisition Corp. on July 1, 2020. The newly formed entity will trade under the ticker symbols 'IMTX' for common stock and 'IMTXW' for warrants on the Nasdaq Capital Market. The deal generated approximately $253 million in proceeds, combining funds from Arya's trust account and PIPE financing from notable healthcare institutional investors. Immatics aims to leverage this capital to advance its cancer immunotherapy programs targeting solid tumors.
FAQ
What is the current stock price of Immatics N.V (IMTX)?
What is the market cap of Immatics N.V (IMTX)?
